Amid increased state and industry regulations, BranchLab provides a new solution for healthcare and pharma brands to reach consumers in a privacy-compliant way

BranchLab, a data science company at the forefront of healthcare advertising, announces the successful closure of a seed funding round led by newark venture partners (nvp). The funding will expedite the development and expansion of BranchLab's innovative AI-driven advertising solutions tailored for the healthcare industry.

Key Highlights:

1. Founding Team and Vision:

   • BranchLab, founded by industry veterans Josh Walsh (CEO), Michael Parkes (President and Chief Revenue Officer), and Chris Cagle (Chief Technology Officer), pioneers advanced AI software for healthcare advertising.
   • The team anticipates and addresses impending challenges arising from cookie and ID deprecation, as well as evolving privacy regulations like My Health My Data.

2. Privacy-First Approach:

   • BranchLab's focus on privacy-safe advertising solutions aligns with the evolving regulatory landscape.
   • The company introduces an "ID-less" solution to bridge the gap between real-world health data and advertising, ensuring patient privacy while enhancing advertising effectiveness.

3. HealthGraph™ Database:

   • Leveraging the HealthGraph™ database, BranchLab aggregates anonymized data from over 300 million US residents and 2.1 million healthcare providers.
   • Machine learning algorithms are applied to create comprehensive audience models, enabling targeted TV advertising and in-flight campaign optimization.

4. Oversubscribed Seed Funding Round:

   • The seed funding round, oversubscribed due to investor confidence, underscores the market demand for innovative healthcare advertising solutions.
   • It positions BranchLab as a frontrunner in the privacy-first advertising landscape and will fuel the company's growth and market expansion.

5. Market Potential:

   • Healthcare advertising is a substantial market, with US spending reaching $23.5 billion in 2023 and projected to exceed $34 billion by 2032 according to IMARC Group.
   • BranchLab's innovative approach aims to capture a significant share of this growing market through privacy-centric advertising solutions.

Investor Perspectives:

1. Vaughn Crowe, Managing Partner at newark venture partners:

   • Expresses confidence in BranchLab's mission to transform healthcare advertising while prioritizing consumer privacy.
   • Emphasizes the company's potential to reshape the advertising ecosystem for pharmaceutical manufacturers.

2. Eric Franchi, General Partner at Aperiam:

   • Applauds BranchLab's commitment to privacy and safety in healthcare advertising amidst industry shifts.
   • Highlights the importance of supporting proven teams like BranchLab in revolutionizing healthcare advertising.

BranchLab's successful seed funding round signifies a significant milestone in its journey to redefine healthcare advertising through advanced AI solutions and a privacy-first approach. With strong investor backing and a seasoned team, BranchLab is poised to lead the evolution of advertising in the healthcare sector, addressing regulatory challenges and enhancing patient privacy while driving advertising effectiveness.